Tafnat Tablet

Introduction

Tafnat is a prescription medication that contains Tenofovir Alafenamide as its active ingredient. It is commonly known by its generic name and is available under the brand name Tafnat. This medication is primarily used for the treatment of certain viral infections.

Uses

Tafnat is prescribed for the following conditions and diseases:

• HIV: It is used as part of antiretroviral therapy to manage HIV infection in adults and adolescents weighing at least 35 kg.
• Chronic Hepatitis B: It is also indicated for the treatment of chronic hepatitis B virus infection in adults.

Dosage and Administration

follow your healthcare provider’s instructions regarding the dosage and administration of Tafnat. The typical recommended dosage for adults and adolescents weighing at least 35 kg is one tablet taken orally once daily, with or without food.

Mechanism of Action

The active ingredient in Tafnat, Tenofovir Alafenamide, belongs to a class of medications called nucleoside reverse transcriptase inhibitors. It works by preventing the replication of the virus and reducing the amount of virus in the body. This helps to slow down the progression of HIV infection and chronic hepatitis B.

Side Effects

Common side effects may include nausea, diarrhea, headache, fatigue, and abnormal liver function tests. Note that not everyone will experience these side effects, and they may vary in severity.

Some serious side effects may occur, although they are rare. These can include severe liver problems, kidney problems, and lactic acidosis. If you experience any severe or persistent side effects, seek medical attention immediately.

Drug Interactions

Tafnat may interact with other medications. Inform your healthcare provider about all the medications, including over-the-counter drugs, supplements, and herbal products, that you are taking. Some common and serious drug interactions may occur, so discuss your full medical history with your healthcare provider.

Precautions

Before taking Tafnat, consider the following precautions:

• Inform your healthcare provider about any known allergies or hypersensitivity to Tenofovir Alafenamide.
• Inform your healthcare provider about any existing medical conditions, especially kidney or liver problems.
• This medication may not be suitable for use during pregnancy or breastfeeding. Consult your healthcare provider for guidance.
• Tafnat should not be used in children weighing less than 35 kg.

Storage

Store Tafnat at room temperature, away from direct sunlight and moisture. Keep it out of reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Take Tafnat exactly as prescribed by your healthcare provider. Do not skip doses or stop taking the medication without consulting your doctor.
• If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Follow any additional instructions provided by your healthcare provider regarding diet, lifestyle changes, and other medications.
• attend regular follow-up appointments with your healthcare provider to monitor the effectiveness and safety of the medication.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Biktarvy 30 mg/120 mg/15 mg film-coated tablets (Health Professionals SmPC) Available at:
• Tenofovir Alafenamide (Drugs.com) [Accessed 14 Jun. 2024] (online) Available at:
• tenofovir alafenamide fumarate tablet (RX) [Accessed 28 Jun. 2024] (online) Available at:
• Tenofovir disoproxil fumarate/Tenofovir alafenamide (MedlinePlus) [Accessed 12 Jun. 2024] (online) Available at:
• Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5. [Accessed 20 Jun. 2024] Available at: